Literature DB >> 12445961

Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy.

Dieter Schmidt1.   

Abstract

Overtreatment is defined here as an unnecessary and excessive drug load in the management of epilepsy leading to a suboptimal risk-to-benefit balance. Pharmacological overtreatment can often be prevented by deciding and counselling carefully about the need for antiepileptic drugs (AEDs) given the limitations of current AEDs. Although AEDs will reduce the incidence of seizures, they have no demonstrated ability to prevent epilepsy in patients at risk or to modify the course of epilepsy in patients following the first seizure. In addition, starting AEDs may not be necessary for control of epileptic seizures induced by precipitation or predisposing factors or for benign epilepsies with rare or mild seizures. Start monotherapy with the chosen first-line AED, initially at low doses titrating up to the low maintenance dose. Avoid drug loading (except for emergency treatment). If seizures continue, titrate to the limit of tolerability which will however, achieve additional seizure control in approximately 20% of patients. If, as in many patients, dosing to the limit of tolerability is not beneficial, the dose should be reduced. Switching to an average dose of another first line AED is another option to prevent overtreatment. Avoid drug overload during add-on therapy by slowly reducing the dose of the first drug in patients having adverse effects, ideally by an amount that the patient does not experience any further adverse effects, if possible, before adding another drug. If the patient does not benefit unequivocally from two-drug therapy within 3 months (and approximately 75% will not benefit), slowly transfer to monotherapy of the second drug and start with a newly chosen AED for add-on. To counteract the propensity to overmedication in chronic epilepsy is not easy. Great benefits, without loss of seizure control, are often gained by slowly reducing the overall drug load.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445961     DOI: 10.1016/s0920-1211(02)00186-9

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  6 in total

1.  Adverse antiepileptic drug effects.

Authors:  Warren T Blume
Journal:  Epilepsy Curr       Date:  2010-01       Impact factor: 7.500

Review 2.  Overtreatment in epilepsy: how it occurs and how it can be avoided.

Authors:  Emilio Perucca; Patrick Kwan
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

4.  Survey on Antiepileptic Drug Therapy in Patients with Drug Resistant Epilepsy.

Authors:  Jun-Sang Sunwoo; Hyunjin Jo; Kyung Wook Kang; Keun Tae Kim; Daeyoung Kim; Dong Wook Kim; Min-Jee Kim; Saeyoon Kim; Woojun Kim; Hye-Jin Moon; Ha Ree Park; Jung-Ick Byun; Jong-Geun Seo; Sung Chul Lim; Min Kyung Chu; Su-Hyun Han; Kyoung Jin Hwang; Dae-Won Seo
Journal:  J Epilepsy Res       Date:  2021-06-30

5.  Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications.

Authors:  William E Rosenfeld; Bassel Abou-Khalil; Sami Aboumatar; Perminder Bhatia; Victor Biton; Gregory L Krauss; Michael R Sperling; David G Vossler; Pavel Klein; Robert Wechsler
Journal:  Epilepsia       Date:  2021-10-11       Impact factor: 6.740

6.  Substitution of anticonvulsant drugs.

Authors:  Bernhard J Steinhoff; Uwe Runge; Otto W Witte; Hermann Stefan; Andreas Hufnagel; Thomas Mayer; Günter Krämer
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.